Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 1 | Breast Cancer Research

Figure 1

From: Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast

Figure 1

Schematic diagram of the study design. Proposed trial design for preoperative chemotherapy in operable breast cancer, exploring in vivo chemosensitivity as a decision-maker for the use of non-cross-resistant salvage chemotherapy in non-responding patients. TAC: Taxotere (docetaxel), Adriblastin (doxorubicin) and cyclophosphamide; NX: Navelbine (vinorelbine) and Xeloda (capecitabine).

Back to article page